Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Trial details
- Registry ID
- NCT07454837
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as BJT-778
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837 | MIRM | Phase 2, Phase 3 | Recruiting | 2027-08-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |